Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Microfluidics International Corporation Announces Second Quarter 2008 Results

Abstract:
Microfluidics International Corporation, (OTCBB: MFIC), an industry-leader in high-shear liquid processing equipment to produce the most uniform and smallest liquid and solid particles available for the biotech, pharmaceutical, chemical, personal care and food industries, today reported financial results for the second quarter of 2008.

Microfluidics International Corporation Announces Second Quarter 2008 Results

NEWTON, MA | Posted on August 12th, 2008

Second Quarter Highlights

-- Recorded highest second quarter revenue in the Company's history of $4.4 million

-- Addressed working capital needs with signing of $2.5 million multi-year revolving credit line

-- Completed executive leadership team with the appointment of a new Executive Vice President and Chief Financial Officer, Chief Technology Officer, and Vice President of Customer Success

-- Finalized three year strategic plan focused on double-digit top line organic global growth

-- Changed name to Microfluidics International Corporation to enhance global branding

For the quarter ended June 30, 2008 the Company reported revenues of $4.4 million, an increase of 23.0% from $3.6 million in the second quarter of 2007 and a negative EBITDA of $(754,000) or $(0.07) per share for the second quarter of 2008 as compared to a negative EBITDA of $(82,000) or $(0.01) per share for the same period in 2007.

Net loss for the second quarter 2008 was $(790,000) or $(0.08) per share as compared to a net loss of $(107,000) or $(0.01) per share for the second quarter ended June 30, 2007.

The Company's order backlog as of June 30, 2008 was $2.7 million compared to backlog of $2.9 million as of June 30, 2007. The decrease in backlog was primarily a result of North American order timing delays of large production machines.

"Our focus on revenue growth, properly building the Company's infrastructure, and rounding out our leadership team remained our top priority this quarter," said Michael C. Ferrara, President and Chief Executive Officer. "We are not pleased with the EBITDA results for the quarter. However, we are in the process of addressing this issue on several fronts and we will align the operating expenses as required on our path to profitability. Strong performance with our large pharmaceutical customers, combined with our initial success in globally expanding our distribution resources are our plans to deliver top line results that will support our growth initiatives."

Brian E. LeClair, Executive Vice President and Chief Financial Officer, added, "Our EBITDA for the second quarter was below our expectations. The loss in the quarter was driven by a decline in our gross margins and an increase in operating expenses. The decline in margins was associated with sales of our lab units which were introduced in the previous quarter at lower margins and higher sales of the custom production machines. We have put corrective plans in place to address the margin decline that should bring our margins back in line with historical levels. Results were also adversely affected by an increase in operating expenses associated with building our leadership team and making investments in our future growth."

####

About Microfluidics International Corporation


              MICROFLUIDICS INTERNATIONAL CORPORATION
          Condensed Consolidated Statements of Operations
    (Unaudited - in thousands, except share and per share amounts)
                  For The Three Months Ended For The Six Months Ended
                          June 30,                  June 30,
                  -------------------------- -------------------------
                      2008          2007        2008        2007
                  ------------- ------------ ------------ ------------
Revenues          $      4,374  $    3,557  $    7,896  $    6,358
Cost of goods
sold                    2,225        1,453        3,834        2,646
                  ------------- ------------ ------------ ------------
Gross profit            2,149        2,104        4,062        3,712
                  ------------- ------------ ------------ ------------
Operating
expenses:
  Research and
  development            572          438        1,062          974
  Selling                1,196          984        2,128        1,808
  General and
  administrative        1,175          805        2,118        1,483
                  ------------- ------------ ------------ ------------
Total operating
expenses                2,943        2,227        5,308        4,265
                  ------------- ------------ ------------ ------------
Loss from
operations              (794)        (123)      (1,246)        (553)
Interest expense            (6)          (1)        (10)          (9)
Interest income            10          17          21          38
                  ------------- ------------ ------------ ------------
Net loss          $      (790) $      (107) $    (1,235) $      (524)
                  ============= ============ ============ ============
Net loss per
common share:
  Basic          $      (0.08) $    (0.01) $    (0.12) $    (0.05)
  Diluted        $      (0.08) $    (0.01) $    (0.12) $    (0.05)
Weighted average
number of common
and common
equivalent
shares
outstanding:
  Basic            10,267,981  10,180,413  10,267,981  10,151,749
  Diluted          10,267,981  10,180,413  10,267,981  10,151,749

-0-

              MICROFLUIDICS INTERNATIONAL CORPORATION
                Condensed Consolidated Balance Sheets
    (Unaudited - in thousands, except share and per share amounts)
                                              June 30,  December 31,
                                                2008        2007
                                            ------------ ------------
ASSETS
Current assets:
  Cash and cash equivalents                  $    1,162  $      756
  Accounts receivable, net of allowance of
  $41 both at June 30, 2008 and December
  31, 2007, respectively                          2,250        2,582
  Inventories                                      2,638        2,353
  Prepaid and other current assets                  688          281
                                            ------------ ------------
    Total current assets                          6,738        5,972
Property and equipment, net                          849          325
Patents and licenses, net                            58          60
                                            ------------ ------------
      Total assets                          $    7,645  $    6,357
                                            ============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
  Revolving credit line                      $    1,012  $      262
  Current maturities of long-term debt and
  obligations under capital lease                    -          65
  Accounts payable                                1,449          129
  Accrued expenses                                1,069          725
  Customer advances                                  464          409
                                            ------------ ------------
    Total current liabilities                    3,994        1,590
                                            ------------ ------------
    Total liabilities                            3,994        1,590
                                            ------------ ------------
Stockholders' equity:
  Common stock; $.01 par value; 20,000,000
  shares authorized; 10,528,427 and
  10,517,178 shares issued; 10,267,981 and
  10,256,732 shares outstanding as of June
  30, 2008 and December 31, 2007,
  respectively.                                    105          105
  Additional paid-in capital                      17,497      17,378
  Accumulated deficit                            (13,263)    (12,028)
  Treasury stock, 260,446 shares, at cost,
  as of June 30, 2008 and December 31, 2007        (688)        (688)
                                            ------------ ------------
    Total stockholders' equity                    3,651        4,767
                                            ------------ ------------
      Total liabilities and stockholders'
        equity                              $    7,645  $    6,357
                                            ============ ============

-0-

              MICROFLUIDICS INTERNATIONAL CORPORATION
          U.S. GAAP TO Non-GAAP Measure Reconciliations and
  Earnings Before Interest, Taxes, Depreciation and Amortization
                              (EBITDA)
          (In thousands, except share and per share amounts)
                        Quarter Ended          Six Months Ended
                          June 30,                  June 30,
                  ------------------------- -------------------------
                      2008        2007        2008        2007
                  ------------------------- -------------------------

Net loss          $      (790) $      (107) $    (1,235) $      (524)
Net interest
income                    (4)        (16)        (10)        (29)
Depreciation and
amortization              40          41          81          83
                  ------------------------- -------------------------
EBITDA (Non-GAAP
Measure)          $      (754) $      (82) $    (1,164) $      (470)
                  ------------------------- -------------------------
Weighted average
number of common
and common
equivalent shares
outstanding:
Basic:              10,267,981  10,180,413  10,267,981  10,151,749
Diluted:            10,267,981  10,180,413  10,267,981  10,151,749
EBITDA per common
share (Non-GAAP
Measure):
Basic:            $    (0.07) $    (0.01) $    (0.11) $    (0.05)
Diluted:          $    (0.07) $    (0.01) $    (0.11) $    (0.05)



Live Webcast

Microfluidics International Corporation will host a webcast at 8:30 a.m. ET today to discuss the quarterly results. To access the webcast, go to the Company's web site, www.mficcorp.com, and click on the webcast icon. If you do not have access to the Internet and wish to listen to the call, dial 888-679-8037 (international callers dial 617-213-4849). The participant passcode for this event is 84046982. An audio replay of the call will be available from 10:30 a.m. ET on Tuesday, August 12th until 11:59 p.m. ET on Tuesday, August 19th. The replay can be accessed by dialing 888-286-8010 (international callers dial 617-801-6888) and entering conference call ID # 91204941.

Safe Harbor for Forward Looking Statements

Certain statements in this press release contain "forward-looking statements." All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws, including the section of this press release entitled "Outlook"; any projections of earnings, revenue or other financial items relating to the Company, any statement of the plans, strategies and objectives of management for future operations; any statements concerning proposed future growth rates in the markets we serve; any statements of belief; any characterization of and the Company's ability to control contingent liabilities; anticipated trends in the Company's businesses; and any statements of assumptions underlying any of the foregoing. Forward-looking statements may include the words "may," "estimate," "intend," "continue," "believe," "expect," "anticipate," and other similar words. Although the Company believes that the expectations reflected in any forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and to inherent risks and uncertainties beyond the control of the Company. These risks and uncertainties include, but are not limited to, risks and uncertainties relating to general economic conditions, geopolitical factors, future levels of general industrial manufacturing activity, future financial performance, market acceptance of new or enhanced versions of the Company's products, the pricing of raw materials, changes in the competitive environments in which the Company's businesses operate, the outcome of pending or future litigation and governmental proceedings and approvals, estimated legal costs, increases in interest rates, the Company's ability to meet its debt obligations, and risks and uncertainties listed or disclosed in the Company's reports filed with the Securities and Exchange Commission, including, without limitation, the risks identified under the heading "Risk Factors" set forth in the Company's Annual Report filed on Form 10-K. The Company does not intend, and undertakes no obligation, to update or alter any forward-looking statements.

EBITDA and Non-GAAP Measures

In addition to the results reported in accordance with generally accepted accounting standards (GAAP) within this release, the Company may reference certain information that is considered a non-GAAP financial measure. Management believes these measures are useful and relevant to management and investors in their analysis of the Company's underlying business and operating performance. Management also uses this information for operational planning and decision-making purposes. Non-GAAP financial measures should not be considered a substitute for any GAAP measures. Additionally, non-GAAP measures as presented by the Company may not be comparable to similarly titled measures reported by other companies.

One specific non-GAAP measure used by the Company is "EBITDA", which is defined as earnings before interest, taxes, depreciation and amortization. Management utilizes the line item non-GAAP operations statement for operational planning and decision-making purposes. A reconciliation of GAAP to non-GAAP financial information discussed in this release is contained in the attached exhibits.

About Microfluidics International Corporation

Microfluidics International Corporation, through its Microfluidics Division, designs, manufactures and distributes proprietary high performance Microfluidizer(R) materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care and food industries. Microfluidics International Corporation applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available and has provided manufacturing systems for nanoparticle products for more than 15 years.

The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to Microfluidics International Corporation equipment customers.

For more information, please click here

Contacts:
Microfluidics International Corporation
Brian E. LeClair
617-969-5452

or
FD Ashton Partners
Michael Cummings
617-897-1532

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Iranian Researchers Present New Model to Strengthen Superconductivity at Higher Temperatures April 19th, 2014

Iranian Researchers Produce New Anti-Cancer Drug from Turmeric April 19th, 2014

'Exotic' material is like a switch when super thin April 18th, 2014

Innovative strategy to facilitate organ repair April 18th, 2014

Microfluidics/Nanofluidics

A*STAR's Simtech collaboration agreements to accelerate the growth and development of the microfluidics industry April 1st, 2014

Dolomite releases novel droplet-on-demand sequencing and droplet generation microfluidic system April 1st, 2014

Heat-Based Technique Offers New Way to Measure Microscopic Particles March 13th, 2014

New partnership between Malvern Instruments and RheoSense brings m-VROCi to industrial markets February 28th, 2014

Announcements

Iranian Researchers Present New Model to Strengthen Superconductivity at Higher Temperatures April 19th, 2014

Iranian Researchers Produce New Anti-Cancer Drug from Turmeric April 19th, 2014

'Exotic' material is like a switch when super thin April 18th, 2014

Innovative strategy to facilitate organ repair April 18th, 2014

Financial Reports

Nanometrics to Announce First Quarter Financial Results on April 29, 2014 April 9th, 2014

Acid folic was used in the production of the nanogel as targeting agent in drug delivery. The nanogel can be used in the treatment of cancer as a stable nanocarrier. Stability of nanocarriers is an important issue in target delivery mechanisms. Most of nanocarriers, due to their March 17th, 2014

Arrowhead Reports Fiscal 2014 First Quarter Financial Results - Conference Call Today at 4:30 p.m. Eastern Time February 4th, 2014

Arrowhead to Report Fiscal 2014 First Quarter Financial Results - Conference Call Scheduled for Tuesday, February 4, 2014 January 28th, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE